AstraZeneca Receives FDA Approval for Fasenra in Hypereosinophilic Syndrome

AstraZeneca today announced that the FDA has approved Fasenra (benralizumab) for the treatment of adults with hypereosinophilic syndrome (HES). HES is a rare, heterogeneous group of disorders characterized by persistent eosinophilia and eosinophil-mediated organ damage. In the Phase 3 NATRON trial, Fasenra demonstrated a statistically significant reduction in HES flares compared to placebo. Fasenra is an anti-IL-5Rα antibody that depletes eosinophils through antibody-dependent cellular cytotoxicity. This approval expands Fasenra's use into HES, adding to its existing approvals in severe eosinophilic asthma and EGPA.